Tapentadol is partially metabolized by the hepatic enzymes CYP2C9, CYP2C19, and CYP2D6 so it innately has interactions with medicines that boost or repress the action/expression of one or more of these enzymes, and with substrates of these enzymes (because of Competitiveness with the enzyme); some enzyme mediators/substrates require dosing adjustments https://wilhelmp023ecz2.azzablog.com/profile